Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Aspirin

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 2 (1)
Phase 3 (1)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT01259856Phase 3CompletedPrimary

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

NCT01259817Phase 2CompletedPrimary

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

Showing all 2 trials

Research Network

Common Treatments

  • Aspirin2
  • Peginterferon Alfa2a2
  • Hydroxyurea1

Active Sponsors

  • National Cancer Institute (NCI)2
  • Myeloproliferative Disorders-Research Consortium2
  • Ronald Hoffman2
  • Roche Pharma AG2

Top Investigators

Related Conditions

  • High Risk Essential Thrombocythemia2

Activity Timeline